U.S. Capital Wealth Advisors LLC Acquires 39,215 Shares of Novo Nordisk A/S $NVO

Key Points

• U.S. Capital Wealth Advisors LLC significantly increased its stake in Novo Nordisk A/S by 447.0% during Q2, acquiring an additional 39,215 shares, raising their total to 47,988 shares valued at $3.3 million.
• A variety of institutional investors have made substantial investments in Novo Nordisk A/S, with Kingstone Capital Partners Texas LLC increasing its holdings by an astounding 301,443.6%, now owning over 10 million shares.
• Several analysts have recently upgraded Novo Nordisk A/S's ratings, with notable changes including a hike from "market perform" to "outperform" by Sanford C. Bernstein, reflecting a positive outlook for the stock.

U.S. Capital Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 447.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,988 shares of the company's stock after acquiring an additional 39,215 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $3,312,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Kingstone Capital Partners Texas LLC grew its position in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock worth $690,560,000 after acquiring an additional 10,001,898 shares during the last quarter. Folketrygdfondet lifted its holdings in Novo Nordisk A/S by 6.9% during the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company's stock worth $661,202,000 after buying an additional 617,974 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Novo Nordisk A/S by 11.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company's stock worth $395,291,000 after buying an additional 576,900 shares in the last quarter. Sustainable Growth Advisers LP lifted its holdings in Novo Nordisk A/S by 3.8% during the 1st quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company's stock worth $384,923,000 after buying an additional 202,443 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Novo Nordisk A/S during the 1st quarter worth $370,272,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NVO. Sanford C. Bernstein raised Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. TD Cowen reduced their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a report on Thursday, July 31st. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Price Performance

NVO opened at $60.70 on Tuesday. The company has a fifty day simple moving average of $56.71 and a 200 day simple moving average of $64.92. The stock has a market cap of $271.03 billion, a P/E ratio of 16.68, a P/E/G ratio of 2.33 and a beta of 0.66. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $127.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.